로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Coagulation factor XI

Coagulation factor XI

요약

Name:Coagulation factor XI
Target Synonym:EC 3.4.21,EC:3.4.21.27,FXI,F11,PTA,Coagulation Factor XI,Plasma Thromboplastin Antecedent,EC 3.4.21.27,Factor XI,Coagualtion Factor XI
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:26
Lastest Research Phase:Approved

제품 리스트 구매

일부의 생물활성 데이터

FXI-C52H3-SPR
 Coagulation factor XI SPR

Abelacimab captured on Protein A Chip can bind Rhesus macaque Coagulation factor XI, His Tag (Cat. No. FXI-C52H3) with an affinity constant of 22.4 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

FXI-H52H5-ELISA
 Coagulation factor XI ELISA

Immobilized Human Coagulation factor XI, His Tag (Cat. No. FXI-H52H5) at 1 μg/mL (100 μL/well) can bind Abelacimab with a linear range of 0.2-8 ng/mL (QC tested).

Synonym Name

Coagulation factor XI,FXI,PTA,F11

Background

Coagulation factor XI is also known as F11, PTA and FXI. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Factor XI is synthesized in the liver and circulates in the plasma as a disulfide bond-linked dimer complexed with high molecular weight kininogen. Selective cleavage of Arg-|-Ala and Arg-|-Val bonds in factor IX to form factor IXa.  Factor XI is converted into XIa via either the contact phase of blood coagulation or thrombin-mediated activation on the platelet surface. The resulting XIa converts factor IX into IXa, which subsequently activates factor X into Xa.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Factor XI concentrate (factor XI deficiency), CSL Behring Approved Csl Behring Llc Australia Factor XI Deficiency Csl Behring Llc 2014-07-01 Factor XI Deficiency Details
Human coagulation Factor XI (LFB) Approved Lfb Biotechnologies Sas Hemoleven EU Factor XI Deficiency Lfb Biotechnologies Sas 1999-07-01 Factor XI Deficiency Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Factor XIa Inhibitor (Bayer) Factor XIa Inhibitor (Bayer) Phase 1 Clinical Blood Coagulation Disorders Details
SKB-336 SKB-336 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Thromboembolism Details
BMS-262084 BMS-262084 Phase 1 Clinical Bristol-Myers Squibb Company Thrombosis Details
IONIS-FXIRX FXI-ASO; ISIS-FXIRX; BAY-2306001; IONIS-FXIRX; ISIS-404071; ISIS-416858 Phase 2 Clinical Ionis Pharmaceuticals Inc Venous Thromboembolism; Thrombosis Details
ONO-7269 ONO-7269 Phase 1 Clinical Ono Pharmaceutical Co Ltd Cerebral Infarction Details
SHR2285 SHR-2285 Phase 2 Clinical Jiangsu Hengrui Medicine Co Ltd Embolism; Venous Thromboembolism; Thrombosis Details
ONO-7684 ONO-7684 Ono Pharmaceutical Co Ltd Details
BMS-962212 BMS-962212; BMS-96221202; BMS-962212-02 Bristol-Myers Squibb Company Details
Osocimab BAY-1213790 Phase 2 Clinical Bayer AG Thromboembolism; Uremia; Kidney Failure, Chronic Details
BAY-1831865 AB-012; BAY-1831865 Phase 1 Clinical Aronora Inc Thrombosis Details
Xisomab 3G3 (Oregon Health & Science University) AB-022; AB-023 Phase 2 Clinical Oregon Health & Science University Solid tumours; Multiple Myeloma; Lymphoma Details
Ir-CPI Ir-CPI Phase 1 Clinical Bioxodes SA Details
Milvexian BMS-986177; JNJ-70033093; JNJ-3093 Phase 2 Clinical Bristol-Myers Squibb Company Kidney Diseases; Stroke; Thromboembolism; Ischemic Attack, Transient; Thrombosis Details
SAL-0104 SAL-0104; SAL0104 Phase 1 Clinical Suzhou Genemen Biotech Co Ltd Embolism; Myocardial Infarction; Venous Thromboembolism; Stroke; Ischemic Attack, Transient; Cardiovascular Diseases; Venous Thrombosis Details
KN060 KN-060 Phase 1 Clinical Thromboembolism Details
EP-7041 EP-7041; HSK36273; HSK-36273; EP7041 Phase 2 Clinical Exithera Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Thrombocytopenia; Thrombosis Details
REGN7508 REGN7508 Phase 1 Clinical Regeneron Pharmaceuticals Inc Details
NIP-003 NIP003 Phase 1 Clinical National Institutes Of Pharmaceutical Research And Development Co Ltd Thromboembolism; Venous Thrombosis Details
Abelacimab MAA-868; NOV-12 Phase 3 Clinical Novartis Pharma Ag Pulmonary Embolism; Venous Thromboembolism; Stroke; Atrial Fibrillation; Venous Thrombosis Details
Fesomersen ION-957943; IONIS-FXI-LRx; BAY-2976217 Phase 2 Clinical Ionis Pharmaceuticals Inc Nephrosis; Thromboembolism Details
REGN-9933 REGN-9933 Phase 2 Clinical Regeneron Pharmaceuticals Inc Venous Thromboembolism Details
BMS-986209 BMS-986209 Phase 1 Clinical Bristol-Myers Squibb Company Details
Asundexian BAY-2433334 Phase 2 Clinical Bayer AG Myocardial Infarction; Thromboembolism; Stroke; Atrial Fibrillation; Hepatic Insufficiency Details
MK-2060 MK-2060 Phase 2 Clinical Merck Sharp & Dohme Corp Uremia; Kidney Failure, Chronic; Thrombosis Details

This web search service is supported by Google Inc.

totop